Suggested remit - To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for untreated CD30-positive peropheral T-cell lymphoma
 
Status Proposed
Process STA 2018
ID number 1586

Provisional Schedule

Expected publication 12 August 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Takeda (brentuximab vedotin)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare Ltd (hydroxydaunorubicin/doxorubicin hydrochloride) (confidentiality agreement not signed, not participating)
  Advanz Pharma (prednisone/prednisolone) (confidentiality agreement not signed, not participating)
  Baxter (cyclophosphamide monohydrate) (confidentiality agreement not signed, not participating)
  Hospira UK Ltd (vincristine) (confidentiality agreement not signed, not participating)
  Janssen-Cilag Ltd (hydroxydaunorubicin/doxorubicin hydrochloride)
  medac UK (hydroxydaunorubicin/doxorubicin hydrochloride) (confidentiality agreement not signed, not participating)
  Pfizer Ltd (hydroxydaunorubicin/doxorubicin hydrochloride, vincristine) (confidentiality agreement not signed, not participating)
  Sandoz Ltd (cyclophosphamide monohydrate) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals Ltd (hydroxydaunorubicin/doxorubicin hydrochloride) (confidentiality agreement not signed, not participating)
  Teva UK Ltd (hydroxydaunorubicin/doxorubicin hydrochloride, vincristine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
19 September 2019 Invitation to participate
24 June 2019 - 23 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance